Viscontour® Serum Med in Hydration of Facial Skin
Launched by TRB CHEMEDICA AG · Apr 3, 2018
Trial Information
Current as of May 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Females ≥ 18 years of age and in good general health condition
- • 2. Signed informed consent
- • 3. Existing Viscontour® Serum Med recommendation (i.a. for hydration, soothing, nourishing and refreshing the complexion and for use in combination with a day cream)
- Exclusion Criteria:
- • 1. Known hypersensitivity to one of the Viscontour® Serum Med components
- • 2. Known pregnancy or lactating females
- • 3. Subjects not capable of contracting and of understanding the nature, risks, significance and implications of the clinical investigation and unable to form a rational intention in the light of these facts
- • 4. Subjects unable to understand informed consent or having a high probability of non compliance to the study procedures and / or non completion of the study according to investigator's judgement (e.g. illiteracy, insufficient knowledge of local language)
About Trb Chemedica Ag
TRB Chemedica AG is a Swiss-based biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of musculoskeletal and autoimmune diseases. With a strong emphasis on research and development, TRB Chemedica is dedicated to advancing its pipeline of products that leverage cutting-edge scientific insights to improve patient outcomes. The company is committed to quality, safety, and efficacy, ensuring that its clinical trials adhere to the highest regulatory standards while fostering collaboration with healthcare professionals and stakeholders in the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials